Profilo
Gideon Gross is the founder of ImmPACT-Bio Ltd.
He is also the founder of GentiBio, Inc.
Posizioni attive di Gideon Gross
Società | Posizione | Inizio |
---|---|---|
GentiBio, Inc.
GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | Fondatore | - |
Precedenti posizioni note di Gideon Gross
Società | Posizione | Fine |
---|---|---|
ImmPACT-Bio Ltd.
ImmPACT-Bio Ltd. BiotechnologyHealth Technology ImmPACT-Bio Ltd. develops therapies to treat cancer. Its chimeric antigen receptor T-cell (CAR-T) therapy addresses the need to differentiate cancerous from non-cancerous tissues. The company was founded by Gideon Gross in April 2017 and is headquartered in Nes Ziona, Israel. | Fondatore | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
ImmPACT-Bio Ltd.
ImmPACT-Bio Ltd. BiotechnologyHealth Technology ImmPACT-Bio Ltd. develops therapies to treat cancer. Its chimeric antigen receptor T-cell (CAR-T) therapy addresses the need to differentiate cancerous from non-cancerous tissues. The company was founded by Gideon Gross in April 2017 and is headquartered in Nes Ziona, Israel. | Health Technology |
GentiBio, Inc.
GentiBio, Inc. BiotechnologyHealth Technology GentiBio, Inc. engages in the development of engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. The company was founded by Adel Nada, David Rawlings, Jane H. Buckner, and Gideon Gross and is headquartered in Seattle, WA. | Health Technology |
- Borsa valori
- Insiders
- Gideon Gross